ID: ALA4169179

Max Phase: Preclinical

Molecular Formula: C25H25FN4O4S2

Molecular Weight: 528.63

Molecule Type: Small molecule

Representations

Canonical SMILES:  CNC(=O)[C@@H](NC(=O)c1ccc(-c2ccc(CSc3nc4scc(C)c4c(=O)[nH]3)c(F)c2)o1)C(C)C

Standard InChI:  InChI=1S/C25H25FN4O4S2/c1-12(2)20(23(33)27-4)28-21(31)18-8-7-17(34-18)14-5-6-15(16(26)9-14)11-36-25-29-22(32)19-13(3)10-35-24(19)30-25/h5-10,12,20H,11H2,1-4H3,(H,27,33)(H,28,31)(H,29,30,32)/t20-/m0/s1

Standard InChI Key:  GWENBFLYSOPNKF-FQEVSTJZSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 528.63

Molecular Weight (Monoisotopic): 528.1301

AlogP: 4.48

#Rotatable Bonds: 8

Polar Surface Area: 117.09

Molecular Species: NEUTRAL

HBA: 7

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 8.69

CX Basic pKa: 1.87

CX LogP: 4.42

CX LogD: 4.40

Aromatic Rings: 4

Heavy Atoms: 36

QED Weighted: 0.23

Np Likeness Score: -1.84

References

1. Fuerst R, Yong Choi J, Knapinska AM, Smith L, Cameron MD, Ruiz C, Fields GB, Roush WR..  (2018)  Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.,  26  (18): [PMID:30249495] [10.1016/j.bmc.2018.08.020]

Source

Source(1):

• Scientific Literature